CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 133 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 3.40 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $76,000 | +123.5% | 22,680 | +100.0% | 0.01% | 0.0% |
| Q3 2020 | $34,000 | -34.6% | 11,340 | 0.0% | 0.01% | -43.8% |
| Q2 2020 | $52,000 | +18.2% | 11,340 | 0.0% | 0.02% | -5.9% |
| Q1 2020 | $44,000 | +2.3% | 11,340 | 0.0% | 0.02% | +6.2% |
| Q4 2019 | $43,000 | -28.3% | 11,340 | 0.0% | 0.02% | -33.3% |
| Q3 2019 | $60,000 | +17.6% | 11,340 | -14.7% | 0.02% | +14.3% |
| Q2 2019 | $51,000 | -19.0% | 13,300 | +8.1% | 0.02% | -22.2% |
| Q1 2019 | $63,000 | +162.5% | 12,300 | 0.0% | 0.03% | +107.7% |
| Q4 2018 | $24,000 | – | 12,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,378,584 | $3,116,000 | 2.30% |
| TANAKA CAPITAL MANAGEMENT INC | 147,993 | $298,000 | 0.90% |
| SOPHROSYNE CAPITAL LLC | 282,500 | $638,000 | 0.56% |
| Ghost Tree Capital, LLC | 200,000 | $452,000 | 0.27% |
| Orbimed Advisors | 1,895,000 | $4,283,000 | 0.05% |
| Financial Architects, Inc | 30,000 | $68,000 | 0.04% |
| Cowen Prime Services LLC | 43,550 | $98,000 | 0.04% |
| Rotella Capital Management, Inc. | 12,300 | $28,000 | 0.03% |
| FEDERATED HERMES, INC. | 3,267,000 | $7,384,000 | 0.02% |
| Baker Brothers Advisors | 569,853 | $1,288,000 | 0.02% |